Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report
April 28, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
Ad hoc announcement pursuant to Art. 53 LR Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report Basel, Switzerland, 28...
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
April 03, 2023 07:00 ET
|
FibroGen, Inc.
- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...
Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
March 30, 2023 08:00 ET
|
Avalyn Pharma Inc.
Seattle, March 30, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today...
Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
March 23, 2023 13:23 ET
|
Avalyn Pharma Inc.
SEATTLE , March 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for life-threatening pulmonary diseases,...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
February 21, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling in Germany/Switzerland Basel, Switzerland, 20 February 2023. Kinarus Therapeutics...
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
January 17, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in...
Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
January 10, 2023 09:00 ET
|
InSilico Medicine
New York, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of...
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
December 06, 2022 01:00 ET
|
Kinarus Therapeutic Holding AG
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report...
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
December 05, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
November 22, 2022 01:00 ET
|
Kinarus Therapeutic Holding AG
Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics...